Voxelotor
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Anemia in Children
Conditions
Sickle Cell Anemia in Children
Trial Timeline
Mar 28, 2022 → Oct 22, 2024
NCT ID
NCT05018728About Voxelotor
Voxelotor is a phase 2 stage product being developed by Pfizer for Sickle Cell Anemia in Children. The current trial status is terminated. This product is registered under clinical trial identifier NCT05018728. Target conditions include Sickle Cell Anemia in Children.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03943615 | Pre-clinical | Completed |
| NCT04724421 | Pre-clinical | Completed |
| NCT06023199 | Phase 2 | Active |
| NCT05018728 | Phase 2 | Terminated |
| NCT04400487 | Approved | Completed |
| NCT04247594 | Phase 2 | Terminated |
| NCT04188509 | Phase 3 | Terminated |
| NCT03573882 | Phase 3 | Terminated |
| NCT03036813 | Phase 3 | Completed |
| NCT02850406 | Phase 2 | Terminated |
Competing Products
20 competing products in Sickle Cell Anemia in Children